Rouen, France, January 27, 2026 – Robocath, a global leader in robotic solutions dedicated to interventional cardiology, today announces the launch of the world’s first FIH (First-In-Human) clinical study evaluating its new robotic system in coronary artery disease.

This second-generation robot, developed thanks to the clinical and technological experience Robocath gained with its first robotic platform – which is already deployed in numerous centers worldwide – integrates unprecedented and unrivaled capabilities designed to meet the increasing demands of complex coronary…

We’re proud to share the publication of the CARE study in the Interventional Neuroradiology Journal:
🧠 “Robotic-assisted carotid artery stenting with R-One™: Feasibility and safety assessment in patients with carotid web lesions”
📖 Now available in open access → Read the full article

This prospective study demonstrates the feasibility and procedural safety of using the R-One™ robotic platform to perform carotid artery stenting (CAS).

💡 With an 86% technical success rate and no intraprocedural complications, these results…

Rouen, France, May 15, 2024 – Robocath, a company that designs, develops and markets innovative robotic solutions to treat cardiovascular and neurovascular diseases, today announces the publication of a new report into current and future expectations for the use of robotics in interventional medicine.

The report sets out the findings from an independent study conducted by Suazio Consulting. It involved 30 interventional cardiologists based in the US, Europe and Asia.

The study reveals growing support for the use of robotics…

Rouen, France, January 9, 2024 – Robocath, a company that designs, develops and markets innovative robotic solutions to treat cardiovascular diseases, today announces the granting of a marketing authorization to distribute its R-One robotic platform in China. This was issued on December 8, by the Chinese National Medical Products Administration (NMPA); making it the first vascular robotic platform to be granted approval in China.

This approval is based in part on the outstanding results achieved in Cathbot’s multicenter clinical trial…

Procedure took place simultaneously in Beijing and Urumqi, carried out entirely via 5G connection with R-One™ robotic platform

Rouen, France, December 13, 2023 – Robocath, a company that designs, develops and markets innovative robotic solutions for treating cardiovascular diseases, today announces it performed a First-in-Human robotic coronary angioplasty from 1,700 miles (2,800 km) away. Two interventional cardiologists, Prof. Yundai Chen in Beijing and Prof. Yining Yang in Urumqi, the capital of the Xinjiang Uygur Autonomous Region, performed the procedure. This world-first, performed…

• 100% clinical success rate: zero complications linked to robot at day 0 and day 30
• R-One™ obtained 86% technical success rate

Rouen and Rennes, France, October 19, 2023 — Robocath, a company that designs, develops and commercializes smart robotic solutions for the treatment of cardiovascular diseases, today announces the results of its ‘CARE’ clinical trial focusing on robotic carotid stenting (1). This study is the first phase in an ambitious research program launched in July…

Rouen, France, May 16, 2023 – Robocath, a company that designs, develops and commercializes smart robotic solutions for the treatment of cardiovascular diseases, today announces the launch of its latest robotic platform – the R-One+. Robocath will showcase this new solution during the upcoming international EuroPCR conference in Paris (France), from May 16 to 19, at the company’s booth (M19, second floor). The R-One+ platform will also be presented in more detail during a dedicated session ‘Robotic PCI: real-life…

Rouen, France, July 20 2022 – Robocath, a company that designs, develops and commercializes innovative robotic platforms for the treatment of vascular diseases, announces today that its joint venture, Cathbot, established in 2020…

Rouen, France, May 18, 2022 – Robocath, a company that designs, develops and commercializes innovative robotic platforms for the treatment of vascular diseases, today presents the results of its R-Evolution clinical study at the international EuroPCR conference. The study, which included 62 patients across six European centers,…

Study results will be presented at EuroPCR conference in Paris, France, May 2022.

Rouen, France, January 11, 2022 – Robocath, a company that designs, develops and commercializes innovative robotic platforms for the treatment of vascular diseases, announces today that it has concluded its ‘R-Evolution’ clinical study.

The study was aimed at assessing the safety and efficacy of the R-OneTM robotic assistance platform. Sixty-two patients across six European hospital centers participated: the university hospitals in Rouen and Caen with Prof. Durand…